183 related articles for article (PubMed ID: 38670731)
1. Impact of Non-steroidal Anti-inflammatory Drugs, Glucocorticoids, and Disease-Modifying Anti-Rheumatic Drugs on Cancer Response to Immune Checkpoint Inhibitor Therapy.
Chan KK; Bass AR
Rheum Dis Clin North Am; 2024 May; 50(2):337-357. PubMed ID: 38670731
[TBL] [Abstract][Full Text] [Related]
2. EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors.
Kostine M; Finckh A; Bingham CO; Visser K; Leipe J; Schulze-Koops H; Choy EH; Benesova K; Radstake TRDJ; Cope AP; Lambotte O; Gottenberg JE; Allenbach Y; Visser M; Rusthoven C; Thomasen L; Jamal S; Marabelle A; Larkin J; Haanen JBAG; Calabrese LH; Mariette X; Schaeverbeke T
Ann Rheum Dis; 2021 Jan; 80(1):36-48. PubMed ID: 32327425
[TBL] [Abstract][Full Text] [Related]
3. Management of rheumatic complications of ICI therapy: a rheumatology viewpoint.
Leipe J; Mariette X
Rheumatology (Oxford); 2019 Dec; 58(Suppl 7):vii49-vii58. PubMed ID: 31816078
[TBL] [Abstract][Full Text] [Related]
4. [Rheumatic immune adverse events related to immune checkpoint inhibitors-(IrAEs related to ICI)].
Tingry T; Massy E; Piperno M; Auroux M; Kostine M; Maillet D; Amini-Adle M; Fabien N; Estublier C; Goncalves D; Girard N; Confavreux CB
Bull Cancer; 2021 Jun; 108(6):643-653. PubMed ID: 33902919
[TBL] [Abstract][Full Text] [Related]
5. Treatment of immune checkpoint inhibitor-induced inflammatory arthritis.
Jeurling S; Cappelli LC
Curr Opin Rheumatol; 2020 May; 32(3):315-320. PubMed ID: 32168068
[TBL] [Abstract][Full Text] [Related]
6. Rheumatic Syndromes Associated With Immune Checkpoint Inhibitors: A Single-Center Cohort of Sixty-One Patients.
Richter MD; Crowson C; Kottschade LA; Finnes HD; Markovic SN; Thanarajasingam U
Arthritis Rheumatol; 2019 Mar; 71(3):468-475. PubMed ID: 30281202
[TBL] [Abstract][Full Text] [Related]
7. Perioperative management of drugs commonly used in patients with rheumatic diseases: a review.
Franco AS; Iuamoto LR; Pereira RMR
Clinics (Sao Paulo); 2017 Jun; 72(6):386-390. PubMed ID: 28658439
[TBL] [Abstract][Full Text] [Related]
8. Immune Checkpoint Inhibitor Related Rheumatological Complications: Cooperation between Rheumatologists and Oncologists.
Pacholczak-Madej R; Kosałka-Węgiel J; Kuszmiersz P; Mituś JW; Püsküllüoğlu M; Grela-Wojewoda A; Korkosz M; Bazan-Socha S
Int J Environ Res Public Health; 2023 Mar; 20(6):. PubMed ID: 36981837
[TBL] [Abstract][Full Text] [Related]
9. Rheumatologic immune checkpoint inhibitor-related adverse events.
Defoe M; Bermas BL
Curr Opin Rheumatol; 2023 May; 35(3):141-148. PubMed ID: 36912045
[TBL] [Abstract][Full Text] [Related]
10. Pharmacoepidemiology and rheumatic diseases: 2001-2002.
Solomon DH; Avorn J
Curr Opin Rheumatol; 2003 Mar; 15(2):122-6. PubMed ID: 12598798
[TBL] [Abstract][Full Text] [Related]
11. Non-steroidal anti inflammatory drugs, glucocorticoids and disease modifying anti-rheumatic drugs for the management of rheumatoid arthritis before and during pregnancy.
Bermas BL
Curr Opin Rheumatol; 2014 May; 26(3):334-40. PubMed ID: 24663106
[TBL] [Abstract][Full Text] [Related]
12. Expert Perspective: Immune Checkpoint Inhibitors and Rheumatologic Complications.
Cappelli LC; Bingham CO
Arthritis Rheumatol; 2021 Apr; 73(4):553-565. PubMed ID: 33186490
[TBL] [Abstract][Full Text] [Related]
13. Guidelines for use of antirheumatic drugs.
Russell AS; Darmawan J; Scott DL; Brooks PM; Hubscher O
J Rheumatol Suppl; 1994 Sep; 41():79-81. PubMed ID: 7799391
[TBL] [Abstract][Full Text] [Related]
14. Comparison of immune checkpoint inhibitor-induced arthritis and reactive arthritis to inform therapeutic strategy.
Jensen AK; Chatzidionysiou K; Torp CK; Sørensen AS; Tenstad HB; Schäfer VS; Kostine M; Jacobsen S; Leipe J; Kragstrup TW
Biomed Pharmacother; 2022 Apr; 148():112687. PubMed ID: 35228067
[TBL] [Abstract][Full Text] [Related]
15. Predictors of Rheumatic Immune-Related Adverse Events and De Novo Inflammatory Arthritis After Immune Checkpoint Inhibitor Treatment for Cancer.
Cunningham-Bussel A; Wang J; Prisco LC; Martin LW; Vanni KMM; Zaccardelli A; Nasrallah M; Gedmintas L; MacFarlane LA; Shadick NA; Awad MM; Rahma O; LeBoeuf NR; Gravallese EM; Sparks JA
Arthritis Rheumatol; 2022 Mar; 74(3):527-540. PubMed ID: 34397169
[TBL] [Abstract][Full Text] [Related]
16. Immune Checkpoint Inhibition-Does It Cause Rheumatic Diseases? Mechanisms of Cancer-Associated Loss of Tolerance and Pathogenesis of Autoimmunity.
Thanarajasingam U; Abdel-Wahab N
Rheum Dis Clin North Am; 2020 Aug; 46(3):587-603. PubMed ID: 32631606
[TBL] [Abstract][Full Text] [Related]
17. Rheumatic immune-related adverse events secondary to anti-programmed death-1 antibodies and preliminary analysis on the impact of corticosteroids on anti-tumour response: A case series.
Mitchell EL; Lau PKH; Khoo C; Liew D; Leung J; Liu B; Rischin A; Frauman AG; Kee D; Smith K; Brady B; Rischin D; Gibson A; Mileshkin L; Klein O; Weickhardt A; Arulananda S; Shackleton M; McArthur G; Östör A; Cebon J; Solomon B; Buchanan RR; Wicks IP; Lo S; Hicks RJ; Sandhu S
Eur J Cancer; 2018 Dec; 105():88-102. PubMed ID: 30439628
[TBL] [Abstract][Full Text] [Related]
18. Patient Voices in Rheumatic Immune-related Adverse Events.
Corps KN; Terry O; Lopez-Olivo MA
Rheum Dis Clin North Am; 2024 May; 50(2):241-254. PubMed ID: 38670723
[TBL] [Abstract][Full Text] [Related]
19. [Do DMARDs contibute to impaired healing after surgery? Should they be discontinued before surgery?].
Glück T; Müller-Ladner U
Dtsch Med Wochenschr; 2007 Sep; 132(37):1901-4. PubMed ID: 17823884
[No Abstract] [Full Text] [Related]
20. [Safety of rheumatic disease drugs at childbearing age].
Zrour-Hassen S; Jguirim M; Aouam K; Korbaa W; Younes M; Bejia I; Touzi M; Bergaoui N
Therapie; 2010; 65(5):465-73. PubMed ID: 21144482
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]